Hisun Pharmaceutical Submitted Clinical Trial Application For Third Generation Insulin Products
This article was originally published in PharmAsia News
Executive Summary
China FDA has accepted Hisun Pharmaceuticals clinical trial applications for recombinant insulin aspart APIs and preparation injections.